Company intelligence / Profile preview

TriLink BioTechnologies

San Diego, California, United States

Ownership: Private
Employees: ~300
Development stage: Other

Overview

TriLink BioTechnologies provides GMP-grade nucleic acids, enzymes, and proprietary CleanCap® capping technology supporting preclinical to commercial development. TriLink products and services have been used in several approved and advanced clinical mRNA-based medicines, including leading COVID-19 vaccines, but TriLink itself does not sponsor proprietary therapeutic programs.

Modalities: mRNA-based drugsSynthetic oligonucleotidePlasmid DNAModified nucleoside triphosphatesEnzyme
Industry: Non-Drug Biotech

Partnerships

Major biopharmaceutical and vaccine companies developing mRNA- and oligonucleotide-based therapeutics (as CDMO supplier/partner, specific names often confidential)

Beyond the preview

Go deeper on TriLink BioTechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriLink BioTechnologies.

Explore the full profile